MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Esperion Therapeutics Company Profile (NASDAQ:ESPR)

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (?)
Ratings Breakdown: 3 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $63.92 (327.82% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
DateFirmActionRatingPrice TargetActions
6/16/2016JMP SecuritiesReiterated RatingBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016Chardan CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Stifel NicolausBoost Price TargetBuy$64.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetOverweight$76.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Needham & Company LLCReiterated RatingPositive$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Bank of AmericaReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015Lake Street CapitalInitiated CoverageBuy$94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015WallachBeth CapitalInitiated CoverageBuy$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2015Citigroup Inc.Lower Price TargetBuy$120.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2015JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Credit SuisseLower Price TargetNeutral$86.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015FIXReiterated RatingaddView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.48)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015($0.54)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214$0.60$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.62)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.82)($0.82)($0.82)
Q2 20161($0.78)($0.78)($0.78)
Q3 20161($1.02)($1.02)($1.02)
Q4 20161($1.28)($1.28)($1.28)
(Data provided by Zacks Investment Research)
Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Esperion Therapeutics (NASDAQ:ESPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
DateHeadline
06/25/16 03:43 PMEsperion Therapeutics Inc. (ESPR) Jumps 6.02% on June 23 - Equities.com
06/24/16 03:58 PMShare Volatility Check for: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph
06/23/16 02:53 PMStock Runners: Ford Motor Company (NYSE:F), Esperion Therapeutics, Inc. (NASDAQ:ESPR), World Fuel Services ... - KC Register
06/23/16 05:28 AMEsperion Therapeutics Inc. (ESPR) Jumps 7.7% on June 20 - Equities.com
06/23/16 05:28 AMEsperion Therapeutics Inc. (ESPR) Drops 5.36% on June 21 - Equities.com
06/21/16 03:41 PMBiotech Gainers: Lpath Inc. (NASDAQ:LPTN), Esperion Therapeutics, Inc. (NASDAQ:ESPR), Amicus Therapeutics, Inc ... - KC Register
06/20/16 03:45 PMWorth Watching Stocks: BioScrip, (NASDAQ:BIOS), Esperion Therapeutics, Inc. (NASDAQ:ESPR), The Goldman Sachs ... - KC Register
06/16/16 08:14 AMEsperion Therapeutics Inc. (ESPR) Jumps 8.43% on June 15 - Equities.com
06/15/16 03:07 PMESPERION THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/06/16 03:45 PMESPERION THERAPEUTICS INC. (NASDAQ:ESPR) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:16 AMEsperion Therapeutics, Inc. (ESPR) Broker Price Targets For The Coming Week - Share Trading News
06/02/16 12:00 PMEsperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/01/16 07:31 AMStock Review and Earnings Check on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - HNN - Stock Review and Earnings Check on Esperion Therapeutics, Inc. (NASDAQ:ESPR)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report quarterly EPS of $-0.8. The company's next earnings report is expected to be ...and more »
05/31/16 09:43 PMEsperion Therapeutics Inc. (ESPR) Jumps 5.01% on May 30 - Equities.com - Esperion Therapeutics Inc. (ESPR) Jumps 5.01% on May 30Equities.comEsperion Therapeutics Inc. (ESPR) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 5.01% to $16.36, representing a gain of $0.78 per share. Some 261,254 shares traded hands on 1,660 trades, compared with an ...and more »
05/30/16 12:03 AMHow Many Esperion Therapeutics Inc (NASDAQ:ESPR)'s Analysts Are Bearish? - HNN - How Many Esperion Therapeutics Inc (NASDAQ:ESPR)'s Analysts Are Bearish?HNNOut of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 85% are positive. Esperion Therapeutics has been the topic of 23 analyst reports since July 28, 2015 according to ...
05/27/16 07:23 PMEsperion Therapeutics Inc. (ESPR) Jumps 5.01% on May 27 - Equities.com - Esperion Therapeutics Inc. (ESPR) Jumps 5.01% on May 27Equities.comEsperion Therapeutics Inc. (ESPR) was among the biggest gainers on the Russell 2000 for Friday May 27 as the stock popped 5.01% to $16.36, representing a gain of $0.78 per share. Some 260,827 shares traded hands on 1,657 trades, compared with an ...and more »
05/26/16 07:13 PMInsiders Are Gradually Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Insiders Are Gradually Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Esperion Therapeutics, Inc. (NASDAQ:ESPR) have increased their position in the stock by 115.15% over the past 6 months. Insiders now own 0.20% of total outstanding shares. There are both legal and ...and more »
05/26/16 07:13 PMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Closes At $15.6300 - RealistInvestor.com - Esperion Therapeutics, Inc. (NASDAQ:ESPR) Closes At $15.6300RealistInvestor.comThe technical analysis of Esperion Therapeutics, Inc. (NASDAQ:ESPR) stock highlights the stock is $-1.1182 points away -6.7247% from its 50-day MA of $16.6283. It is $-3.3794 or -17.8904% away $18.8895, the 200-day Moving Average (MA) of stock.Esperion Therapeutics, Inc. (NASDAQ:ESPR): Analysts Quick Take on EarningsNews Tribuneall 8 news articles »
05/25/16 12:29 AMEarnings Review and Stock Rundown for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Earnings Review and Stock Rundown for Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Esperion Therapeutics, Inc. (NASDAQ:ESPR ...and more »
05/24/16 07:10 PMTarget Check and Stock Performance Recap Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Target Check and Stock Performance Recap Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Esperion Therapeutics, Inc.and more »
05/22/16 11:32 PMStock Rating Review for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Stock Rating Review for Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.38 on shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR). Covering ...and more »
05/21/16 06:32 PMEsperion Therapeutics Inc. (ESPR) Jumps 5.82% on May 20 - Equities.com - Esperion Therapeutics Inc. (ESPR) Jumps 5.82% on May 20Equities.comEsperion Therapeutics Inc. (ESPR) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 5.82% to $15.08, representing a gain of $0.83 per share. Some 213,527 shares traded hands on 1,609 trades, compared with an ...and more »
05/19/16 06:59 PMInsiders Are Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Insiders Are Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Esperion Therapeutics, Inc. (NASDAQ:ESPR) have increased their position in the stock by 106.74%. Insiders now own 0.20% of total outstanding shares. There are both legal and illegal types of insider trading.and more »
05/18/16 11:26 AMShare Performance and Target Price Review for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Share Performance and Target Price Review for Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsDuring the most recent trading session, Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares traded -5.61%. Tracking the stock price in relation to moving averages may provide enhanced perspective on stock performance. After a recent look, the stock has ...and more »
05/18/16 11:26 AMShare Recap and Earnings Focus on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Share Recap and Earnings Focus on Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Esperion Therapeutics, Inc.and more »
05/17/16 11:53 PMEsperion Therapeutics Inc. (ESPR) Jumps 5.51% on May 16 - Equities.com - Esperion Therapeutics Inc. (ESPR) Jumps 5.51% on May 16Equities.comEsperion Therapeutics Inc. (ESPR) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 5.51% to $15.52, representing a gain of $0.81 per share. Some 201,780 shares traded hands on 1,602 trades, compared with an ...and more »
05/16/16 12:24 PMConsensus Rating Review for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Hints and News - Consensus Rating Review for Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.38 on shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/13/16 07:19 PMPrice Review of Stocks: Antares Pharma, Inc. (NASDAQ:ATRS) , Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Street Updates - Price Review of Stocks: Antares Pharma, Inc. (NASDAQ:ATRS) , Esperion Therapeutics, Inc. (NASDAQ:ESPR)Street UpdatesIn the past trading session, Esperion Therapeutics, Inc. (NASDAQ:ESPR) highlighted downward shift of -3.48% or -0.52 points to $14.41. The company traded a volume of 327.39 thousand shares under average volume of 432.74 thousand shares. Trailing ...and more »
05/12/16 07:44 PMBroker Roundup For Esperion Therapeutics, Inc. (ESPR) - Share Trading News - Broker Roundup For Esperion Therapeutics, Inc. (ESPR)Share Trading NewsThe share price of Esperion Therapeutics, Inc. (ESPR) was down -3.55% during the last trading session, with a day high of 15.22. 116546 shares were traded on Esperion Therapeutics, Inc.'s last session. The stock's 50 day moving average is 17.14 and its ...and more »
05/10/16 12:04 PMESPERION THERAPEUTICS, INC. Financials -
05/10/16 09:50 AM[$$] Three Big Pharma Stocks Headed Higher -
05/09/16 07:10 PMCheck on Analyst Ratings Esperion Therapeutics, Inc. (NASDAQ:ESPR) - B.O.D.Y Confidential - Check on Analyst Ratings Esperion Therapeutics, Inc. (NASDAQ:ESPR)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1.38 on shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 ...and more »
05/07/16 11:55 PMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Boasts An Average Rating Of 4.25 - Stocks Daily - Esperion Therapeutics, Inc. (NASDAQ:ESPR) Boasts An Average Rating Of 4.25Stocks DailyAlpha One applies algorithm-based analytics for assessing a stock sentiment as per the published released on web channels. In this evaluation process, the group accesses the most relevant news platforms on a daily basis. Esperion Therapeutics, Inc.and more »
05/07/16 06:31 PMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Basic Consolidated EPS At $-2.2609 - Stocks Daily - Esperion Therapeutics, Inc. (NASDAQ:ESPR) Basic Consolidated EPS At $-2.2609Stocks DailyThe basic EPS generating from continuing operations as announced by Esperion Therapeutics, Inc. (NASDAQ:ESPR) for the period ended 2015-12-31 was $-2.2609. For the quarter ended 2015-12-31, this number was $-2.2609. For any specified firm's ...Esperion Therapeutics, Inc. (ESPR) Updated Broker RatingsRisers & FallersEsperion Therapeutics Inc (ESPR) Lifted to Hold at Zacks Investment ResearchWeb Breaking NewsEsperion Therapeutics Incorporated (NASDAQ:ESPR) Sellers Covered 9.37% of Their ShortsB.O.D.Y Confidentialall 4 news articles »
05/06/16 07:28 PMEsperion Therapeutics Incorporated (NASDAQ:ESPR) Sellers Covered 9.37% of Their Shorts - B.O.D.Y Confidential - Esperion Therapeutics Incorporated (NASDAQ:ESPR) Sellers Covered 9.37% of Their ShortsB.O.D.Y ConfidentialThe short interest to Esperion Therapeutics Incorporated's float is 29.21%. The stock decreased 0.14% or $0.02 during the last trading session, hitting $14.35. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 39.17% since September 30, 2015 and is ...and more »
05/05/16 08:18 PMEsperion Therapeutics Inc. (ESPR) Drops 7.71% on May 04 - Equities.com - Esperion Therapeutics Inc. (ESPR) Drops 7.71% on May 04Equities.comEsperion Therapeutics Inc. (ESPR) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 7.71% to $14.37, a loss of $-1.2 per share. Starting at an opening price of $15.35 a share, the stock traded between $13.50 and $15.44 ...and more »
05/05/16 12:34 AMEarnings Outlook on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - B.O.D.Y Confidential - Earnings Outlook on Esperion Therapeutics, Inc. (NASDAQ:ESPR)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Esperion Therapeutics, Inc. (NASDAQ:ESPR)'s next earnings release which is expected to be posted on or around 2016-05-05. Sell-side research firms on Wall Street are expecting that the company will post EPS ...and more »
05/04/16 07:19 PMCompany Update (NASDAQ:ESPR): Esperion Therapeutics Inc Reports First Quarter 2016 Financial Results - Smarter Analyst - Web Breaking NewsCompany Update (NASDAQ:ESPR): Esperion Therapeutics Inc Reports First Quarter 2016 Financial ResultsSmarter AnalystEsperion Therapeutics Inc (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today ...Esperion Therapeutics Inc (ESPR) Sees Strong Trading Volume After Earnings BeatWeb Breaking NewsEsperion Therapeutics reports 1Q lossMoney Morningall 5 news articles »
05/04/16 07:31 AMESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
05/04/16 07:30 AMEsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results - [at noodls] - May 4, 2016 ANN ARBOR, Mich., May 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density ...
05/04/16 07:16 AMEsperion Therapeutics reports 1Q loss -
05/02/16 08:55 PMAverage Analyst Rating for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - B.O.D.Y Confidential - Average Analyst Rating for Esperion Therapeutics, Inc. (NASDAQ:ESPR)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.38 on Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
04/30/16 07:13 PMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Has An Impact Score Of 100 - Stocks Daily - Esperion Therapeutics, Inc. (NASDAQ:ESPR) Has An Impact Score Of 100Stocks DailyEsperion Therapeutics, Inc. (NASDAQ:ESPR) has been given a -0.109 daily sentiment score for the related articles published on web today. Alpha One offer algorithm-based analytics, which can help state stock sentiment based on the content published on ...and more »
04/26/16 07:20 PMShare Performance and Target Price Review Esperion Therapeutics, Inc. (NASDAQ:ESPR) - B.O.D.Y Confidential - Share Performance and Target Price Review Esperion Therapeutics, Inc. (NASDAQ:ESPR)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) ended up with a move of -4.55%. Sell-side analysts have given a consensus target price of $49.69 on company shares. Target price projections may differ greatly ...and more »
04/26/16 07:20 PMCurrent Price Targets For Esperion Therapeutics, Inc. (ESPR) - Risers & Fallers - Current Price Targets For Esperion Therapeutics, Inc. (ESPR)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Esperion Therapeutics, Inc. (ESPR). The latest broker reports which are currently outstanding on Tuesday 26th of April state 0 analysts have a rating of “strong buy”, 0 ...and more »
04/25/16 09:54 PMEsperion Therapeutics Inc Declines A lot Today, Is Now One of The Worst Performer - The Post - Esperion Therapeutics Inc Declines A lot Today, Is Now One of The Worst PerformerThe PostThe stock of Esperion Therapeutics Inc (NASDAQ:ESPR) is a huge mover today! The stock is down 6.14% or $1.18 after the news, hitting $18.11 per share. About 201,319 shares traded hands. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined ...
04/03/16 10:05 AMSome People Really Can't Take Statins For High Cholesterol, Scientists Prove -
03/11/16 09:03 PMESPERION 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR - [GlobeNewswire] - NEW ORLEANS, March 11, 2016-- Kahn Swick& Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only ...
03/11/16 08:35 PMINVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc. - [Business Wire] - Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. for potential violations of federal securities laws and breaches of the Esperion Board’s fiduciary duties.
03/11/16 08:30 AMMarch 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Esperion Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline - [Business Wire] - Law Offices of Howard G. Smith reminds investors of the upcoming March 14, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Esperion Therapeutics, Inc.
About Esperion Therapeutics

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company's primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Company's lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ESPR
  • CUSIP:
Key Metrics:
  • Previous Close: $14.94
  • 50 Day Moving Average: $16.18
  • 200 Day Moving Average: $17.34
  • P/E Ratio: N/A
  • P/E Growth: -0.19
  • Market Cap: $336.63M
  • Current Quarter EPS Consensus Estimate: $-3.76 EPS
Additional Links:
Esperion Therapeutics (NASDAQ:ESPR) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha